EACS2023: 311 Real-life data of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults living with VIH-1. 48-96 weeks results of RETROBIC study J. Troya , R. Micán , G. Pousada , C. Galera , J. Sanz , I. Santos , C. Dueñas , N. Cabello , C. Martín , M.J. Galindo , M.Á. Garcinuño , C. Hernández , R. Pedrero-Tomé , D. Ortega , S. Estévez , G. Lebón , L. Buzón , RETROBIC Hospital Universitario Infanta Leonor, Madrid, Spain, Hospital Universitario La Paz, Madrid, Spain, Hospital Álvaro Cunqueiro, Vigo, Spain, Hospital L´Arrixaca Murcia, Murcia, Spain, Hospital Príncipe de Asturias, Madrid, Spain, Hospital Universitario La Princesa, CIBERINFEC Instituto de Salud Carlos III, Madrid, Spain, Hospital de Valladolid, Valladolid, Spain, Hospital Clínico de Madrid, Madrid, Spain, Complejo Asistencial de Zamora, Zamora, Spain, Hospital Clínico de Valencia, Valencia, Spain, Complejo Asistencial de Ávila, Ávila, Spain, Fundación de Investigación e Innovación del Hospital Universitario Infanta Leonor y del Sureste, Madrid, Spain, Hospital de Burgos, Burgos, Spain General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH) with high efficacy and safety rates in long-term data of clinical trials. However, data regarding efficacy and immune status restoration in big real-life cohorts of long-time treated patients are needed. Method: We performed a multicenter, non-controlled, retrospective study suppressed PLWH switching to B/F/TAF. We evaluated the efficacy and immune status regarding CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 48 and 96 weeks after the switch. Results: The study comprised 1967 persons from 13 hospitals in Spain, of whom 80.0% were men and had a median age of 51.0 [42.0–57.0] years. The median time of HIV infection was 18.0 [10.0–27.0] years. AIDS diagnoses were made in 22.4% of cases. Virological failure was registered in 13 (0.66%) persons [available data of viral suppression at 48 weeks in 1779 patients: 95.6% (<50 copies/ml); 98.4% (<100 copies/ml); 99.2% (<200 copies/ml), and at 96 weeks in 1359 patients: 96.1%, 98.8%, and 99.5%% respectively]. No resistance mutations were found. Median CD4 at switching to B/F/TAF was 694.2 [486 – 911]. In week 48, we found a decrease in CD8+ count of -25 cells/mm (-242 – 144) and an increase in CD4+ count of 39 (- 100 – 163), and in week 96, a decrease in CD8+ count of -22 cells/mm (-238 – 183) and an increase in CD4+ count of 38 (-135 – 220). CD4/CD8 ratio increased by 0.01 (-0.05 – 0.10) and -0.03 (-0.08 – 0.18) in weeks 48 and 96, respectively . In AIDSdiagnosed patients, a significant increase in the CD4+ count of 35 (-88 – 148) cells/mm was found at week 48 and week 96 of 40 (-119 – 216) cells/mm ; p=0.050. Conclusions: In long-term virologically-controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status during weeks 48 and 96 after switching. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 11 5 12 2 1 1 13 1 2 3 4 5 6 7 8 9 10 11 12 13 3 3 3 3 100 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=